SignalRx Pharmaceuticals Inc., Crystec Ltd., and ADYA Consulting SAGL are pleased to announce a new collaboration to develop an inhaled dry powder formulation of SF2523 for the treatment of pulmonary fibrosis, lung cancer and SARS-CoV-2 related illnesses.
Nanoform Finland Plc, an innovative nanoparticle medicine enabling company, today announced further positive interim results from its ongoing clinical study.
CatSci further strengthens its material science, analytical science and preformulation capabilities with a £3 million investment
CatSci, a scientifically-led, commercially-minded and award-winning innovation partner for medicines development, is expanding its capabilities in material science, analytical science and preformulation studies to better serve its customers’ needs.
The agreed and non-exclusive collaboration is intended to assess the utility of Nanoform’s latest nanoparticle platform technology for biologic drugs.
Nanoform Finland Plc (“Nanoform”), an innovative nanoparticle medicine enabling company, today announced positive interim results from its clinical study. The faster absorption data implies that small particles can indeed be powerful.